Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating on November 17.
Graig Suvannavejh has given his Buy rating to Vigil Neuroscience Inc’s stock due to a combination of factors that he believes to be promising for the company’s future. These factors include the positive interim Phase 2 data for their lead asset, VGL101, in patients with ALSP, a rare and currently untreatable neurodegenerative disease. Despite the early nature of these data and their somewhat complex nature, Suvannavejh found the results encouraging when viewed from a longer-term perspective.
Furthermore, Suvannavejh was encouraged by the new data on VGL101, including findings from the ILLUMINATE study, the first-ever natural history study in patients with axonal spheroids and pigmented glia. He also highlighted the positive first interim Phase 2 IGNITE study data in ALSP patients. Suvannavejh was particularly optimistic about the safety and tolerability of iluzanebart, with no treatment-emergent adverse events or serious adverse events reported, and no discontinuations. In addition, the secondary endpoints based on biomarkers demonstrated target engagement. All of these factors contribute to his belief that Vigil Neuroscience presents a positive investment opportunity, hence the Buy rating.
In another report released on November 17, JMP Securities also reiterated a Buy rating on the stock with a $23.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vigil Neuroscience Inc (VIGL) Company Description:
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.
Read More on VIGL:
- Vigil Neuroscience announces interim data from IGNITE trial
- Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
- Vigil Neuroscience reports Q3 EPS (53c), consensus (57c)
- Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
- Arm initiated, SQM downgraded: Wall Street’s top analyst calls
